35th Hemophilia Symposium Hamburg 2004 (eBook)

Epidemiology.- HIV Infection and Causes of Death in Patients with Hemophilia in Germany (Year 2003/2004 Survey).- Hemophilia Registry of the Medical Committee of the Swiss Hemophilia Association — Update and Annual Survey 2004.- Risk of Infections and Inhibitors in Hemophilia.- Update on the Safety of Clotting Factors, Mainly Regarding the Risk of Transmission of vCJD (Variant Creutzfeldt Jakob Disease).- nvCJD and Blood Products in the UK.- Mutation Type Dependent Inhibitor Risk — a Single Center Study on 432 Patients with Severe Hemophilia A.- Inhibitor Incidence in Previously Untreated Patients (PUPs) with Hemophilia A and B. A Prospective Multi-Center Study of the Pediatric Committee of the German, Swiss and Austrian Society for Thrombosis and Hemostasis Research (GTH).- ADVATE Inhibitor Risk Profile: 18 Months post-Licensure.- EACH-Registry: An European Registry for Acquired Hemophilia.- Elective Orthopedic Surgery for Hemophilia Patients with Inhibitors.- Chronic Synovitis and Long-term Results of Orthopedic Treatment.- Results after Total Knee and Hip Replacement in Patients with Hemophilia A — A Single Center Experience.- Motion Analysis Epidemiology in Hemophilic Children.- Radiosynoviorthesis in Hemophilic Arthropathy — A Single Center Experience.- Laboratory Diagnostics: Coagulation Factor, Inhibitors, Monitoring.- Individual Therapy of Hemophilia — New Laboratory Methods Considering Platelets.- Epitope Mapping during FVIII Inhibitor Elimination with Rituximab Reveals Conformational Epitopes on FVIII and Identifies Small Molecules Blocking Inhibitor and Targeting B Cells.- Lack of Factor VIII Expression Represents a Novel Mechanism Leading to Hemophilia A.- Pediatric Hemostaseology.- Effects of the Factor V G1691 A Mutation and the Factor II G20210A Variant on the Clinical Expression of Severe Hemophilia A (< 2%) in Children — Results of a Multicenter Study.- Continuous Infusion of Factor Concentrates in Children with Hemophilia A in Comparison to Bolus Injections.- Decreased Clotting Factor Activity (VIII, IX, XI, and XII) due to Inhibitors with Lupus-like Activity in Childhood.- Free Lectures.- Effect of Activated Recombinant Coagulation Factor VII on the Function of Glycoprotein IIb/IIIa-Inhibited Platelets in Vitro.- Mutation Analysis in Hereditary Angioedema Identifies Patients at Risk for Developing Acute and Life Threatening Edema.- Recurrent Mutation in ADAMTS13 Gene as a Cause of a Hereditary Thrombotic Thrombocytopenic Purpura in the Czech Republic.- Clinical Manifestations of Patients with Dysfibrinogenemia.- Case Report of a FXIII Inhibitor in a 77-year-old Patient.- Poster.- The ABC’s of Hemophilia.- The Long Journey to Being Diagnosed as a Carrier of Hemophilia A — A Woman with Abnormally Prolonged Bleeding after Myocardial Infarction.- Clinical Investigation of Orthopedic Outcome in Patients with Severe Hemophilia — Advantage of an Early Prophylactic Treatment?.- The Relevance of Thrombophilic Risk Factors on Bleeding Tendency in Hemophilia A Patients.- Magnetic Field Therapy in Patients with Severe Hemophilia — Motion Analysis and Quality Control.- The Clinical Course of two Patients Receiving High Dose Factor VIII — Replacement Therapy.- Determination of the Factor VIII Plasma Activity of Hemophilia A Patients Treated with a New Recombinant Factor VIII Concentrate.- Socio-Economic Aspects of Hemophilia Treatment in Romania.- Immunosuppressive Treatment in Acquired von-Willebrand’s Syndrome.- HCV-Infection in HIV-Infected and Non-Infected People with Hemophilia — A Retrospective Study: Medical Aspects.- HCV-Infection in HIV-Infected and Non-Infected People with Hemophilia — A Retrospective Study: Psychosocial Aspects.- Testing Factor VIII Activity by Using the Chromogenic Assay in Carriers of Hemophilia A.- Hip Replacement in Hemophilic Patients — A 30 Years Single Center Experience.- Successful Therapy with anti CD20 Monoclonal Antibody Rituximab in Patients with Acquired Hemophilia against Factor VIII.- Unusual Prolonged Course of an Immune Tolerance Therapy (ITT) in a Patient with Severe Hemophilia A and a High-Titer Inhibitor Development.- Successful Major Surgery with Minimal Dosage of rFVIIa in a Hemophilia A Patient with High Level of Alloantibodies to Factor VIII.- Inhibitor Development after Continuous Infusion of Factor VIII: A Retrospective Study in Germany.- Inhibitors in PTP’S: A Retrospective Study in Germany.- Elective Orthopedic Surgery in Inhibitor Patients — the Frankfurt Concept.- The Frequency of Venous Thromboembolism in Women with FV Leiden in Association with Pregnancy and Puerperium.- Spectrum of Molecular Defects and Mutation Detection Date in Patients with Severe Hemophilia A.- Hemophilia Patients and Prothrombotic Gene Mutation.- ?A1a82Gly Represents a Common Fibrinogen Chain Variant in Caucasians.- A Novel Mutation (Asp36Tyr) in the Vitamin K Epoxide Reductase Complex Subunit 1 Gene (VKORC1) Causes Increased Phenprocoumon Requirement.- Denaturing High Performance Liquid Chromatography Represents an Efficient Technique for Detection of Heterozygous Large Deletions in Antithrombin Gene.- Recurrent Coronary Stent Thrombosis in a Patient with Combined Aspirin and Clopidogrel Resistance.- Coagulation Factor XIII Mutation Profile: Update 2004.- Site-Directed Mutagenesis of VKORC1, the Target Protein of Coumarin-Type Anticoagulants.- Treatment of Dilution Coagulopathy by Fibrinogen and Platelet Concentrates.- Pathogenesis of Hepatic Veno-Occlusive Disease in Patients Undergoing Hematopoietic Stem Cell Transplantation.